الفهرس | Only 14 pages are availabe for public view |
Abstract The aim of using Neoadjuvant chemotherapy has exceeded down staging locally advanced cases and the ability to do BCS especially in the era of advanced techniques of oncoplastic surgery. NACT is now accepted to be used in all cases where chemotherapy was indicated at diagnosis for the aim of improving DFS and OS. Another benefit of NACT is in vivo sensitivity testing of the response of various breast cancer molecular subtypes to different chemotherapy regimens. The criteria to assess pathologic response have not been standardized yet; however, in the majority of the studies, the degree of response to treatment has a strong correlation with survival Metformine is oral hypoglycemic drug commonly used to treat type 2 DM. The anti-neoplastic effect of metformin involves both direct (insulinindependent) and indirect (insulin-dependent) actions of the drug. We did a prospective control study which included 59 female patients with stage II,III breast cancer eligible for neoadjuvant chemotherapy . Only triple negative subtype was excluded from our study. Our sample was divided into group (A) with 27 patients represented metformine group received standard NAC with metformine 850mg BID, and group (B) included 32 patients represented control group and received only neoadjuvant chemotherapy. The main finding of our study is that the rate of complete pathological response was 14.8% (4 patients) in group (A) ”metformin group” versus 6.3% (2 patients) in group (B) ”non-metformin group” with a P-value of 0.39. When we used residual cancer burden scoring system in the analysis of pathological response and combined class (RCB 0/1/2) versus RCB class 3 |